We have located links that may give you full text access.
LOXO-292 Reins In RET-Driven Tumors.
Cancer Discovery 2018 August
LOXO-292, a selective and potent RET inhibitor, led to tumor shrinkage in RET fusion-positive and RET -mutant cancers alike, according to phase I data reported at the 2018 American Society of Clinical Oncology Annual Meeting.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app